Bioethics, Psychedelic Therapy Abuse, and the Risk of Ethics Washing
What challenges arise for bioethicists when taking on commissions to work for organizations that are emerging out of the psychedelic underground?

What challenges arise for bioethicists when taking on commissions to work for organizations that are emerging out of the psychedelic underground?

This piece identifies three interrelated topics that warrant scrutiny as drivers of psychedelic racial health inequities.

Historic and contemporary discussions on psychedelic and MDMA research largely ignore theories on power, control, and abusive interpersonal relationships.

Following psychedelic integration therapy, should the same lead therapist continue psychotherapy with their patients?

Here, we examine hype in the context of a perennial tension at the heart of patenting communication: between advertising innovation and keeping it secret.

In short, 109’s creators’ stated intent to make psilocybin therapy accessible to help the growing mental health care crisis has resulted in a policy that doesn’t allow for any of it.

A brief sketch of the potential for Rights of Nature legislation to safeguard sacred plant medicines by recognizing them as rights holders unto themselves.

Psychedelic science appears to ignore many of the lessons learned from decades of research in other fields.

As a historian of psychoactive pharmaceuticals in the 20th century U.S., I see history rhyming in potentially dangerous ways in the current psychedelic boom.
